Plasma Fibrinogen, Ambulatory Blood Pressure, and Silent Cerebrovascular Lesions The Ohasama Study by Aono  Yoko et al.
Plasma Fibrinogen, Ambulatory Blood Pressure,
and Silent Cerebrovascular Lesions The Ohasama
Study
著者 Aono  Yoko, Ohkubo  Takayoshi, Kikuya 
Masahiro, Hara  Azusa, Kondo  Takeo, Obara 
Taku, Metoki  Hirohito, Inoue  Ryusuke,
Asayama  Kei, Shintani  Yoriko, Hashimoto 
Junichiro, Totsune  Kazuhito, Hoshi  Haruhisa,
Satoh  Hiroshi, Izumi  Shin-Ichi, Imai Yutaka
journal or
publication title
Arteriosclerosis, Thrombosis, and Vascular
Biology
volume 27
number 4
page range 963-968
year 2007
URL http://hdl.handle.net/10097/51532
doi: 10.1161/01.ATV.0000258947.17570.38
Yutaka Imai
Hashimoto, Kazuhito Totsune, Haruhisa Hoshi, Hiroshi Satoh, Shin-Ichi Izumi and
Obara, Hirohito Metoki, Ryusuke Inoue, Kei Asayama, Yoriko Shintani, Junichiro 
Yoko Aono, Takayoshi Ohkubo, Masahiro Kikuya, Azusa Hara, Takeo Kondo, Taku
Lesions : The Ohasama Study
Plasma Fibrinogen, Ambulatory Blood Pressure, and Silent Cerebrovascular
ISSN: 1524-4636 
Copyright © 2007 American Heart Association. All rights reserved. Print ISSN: 1079-5642. Online
7272 Greenville Avenue, Dallas, TX 72514
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association.
doi: 10.1161/01.ATV.0000258947.17570.38
February 1, 2007
2007, 27:963-968: originally published onlineArterioscler Thromb Vasc Biol 
http://atvb.ahajournals.org/content/27/4/963
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
http://www.lww.com/reprints
Reprints: Information about reprints can be found online at 
  
journalpermissions@lww.com
410-528-8550. E-mail: 
Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
http://atvb.ahajournals.org//subscriptions/
Biology is online at 
Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular
 at TOHOKU UNIVERSITY on September 1, 2011http://atvb.ahajournals.org/Downloaded from 
Plasma Fibrinogen, Ambulatory Blood Pressure, and Silent
Cerebrovascular Lesions
The Ohasama Study
Yoko Aono, Takayoshi Ohkubo, Masahiro Kikuya, Azusa Hara, Takeo Kondo, Taku Obara,
Hirohito Metoki, Ryusuke Inoue, Kei Asayama, Yoriko Shintani, Junichiro Hashimoto,
Kazuhito Totsune, Haruhisa Hoshi, Hiroshi Satoh, Shin-Ichi Izumi, Yutaka Imai
Objective—Twenty-four–hour ambulatory blood pressure (24-hour ABP) values are considered a powerful predictor of
stroke. Silent cerebrovascular lesions are associated with an increased risk of stroke. Because fibrinogen is a major
determinant of plasma viscosity, an elevated fibrinogen level might also be associated with stroke risk. We evaluated
the association of 24-hour ABP and plasma fibrinogen levels with the risk of silent cerebrovascular lesions (white matter
hyperintensity and lacunar infarct) detected by MRI.
Methods and Results—The study cohort comprised 958 individuals from the general population of Ohasama, a rural
Japanese community. Multiple logistic regression analysis adjusted for age, sex, smoking and drinking status, use of
antihypertensive medication, body mass index, 24-hour ABP, and a history of hypercholesterolemia, diabetes mellitus,
and atrial fibrillation demonstrated that each 1-SD increase in fibrinogen level was associated with a significantly
increased risk of silent cerebrovascular lesions (odds ratio, 1.26; P0.001). The 24-hour ABP was also significantly and
independently associated with the risk of silent cerebrovascular lesions. Even when 24-hour ABP values were within
normal range (135/80 mm Hg), elevated fibrinogen levels were associated with an increased risk of silent
cerebrovascular lesions. Fibrinogen and 24-hour BP had additive effects on silent cerebrovascular lesions.
Conclusion—The 24-hour ABP and plasma fibrinogen levels were closely and independently associated with the risk of
silent cerebrovascular lesions including white matter hyperintensity and lacunar infarct. (Arterioscler Thromb Vasc
Biol. 2007;27:963-968.)
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Silent cerebrovascular lesions as white matter hyperinten-sity (WMH) and lacunar infarcts are frequently observed
on MRI scans of elderly individuals. Silent cerebrovascular
lesions constitute an independent predictor of the risk of
symptomatic stroke,1,2 and are associated with cognitive
impairment or dementia.3
Fibrinogen is involved in primary hemostasis, platelet
aggregation, and leukocyte–endothelial cell interaction, and
it is the major determinant of whole blood and plasma
viscosity.4,5 Elevated fibrinogen levels induce a state of
hypercoagulability,6,7 and may reflect the progression of
atherosclerosis.
Growing evidence indicates that fibrinogen is a risk
factor for coronary heart disease.8 –10 A large meta-analy-
sis11 has shown close associations between elevated
plasma fibrinogen levels and the risk of coronary heart
disease and stroke mortality. However, findings regarding
the incidence of stroke,12–14 as well as the relationship
between fibrinogen and silent cerebrovascular lesions15–18
are inconsistent. The latter studies included patients with a
history of cerebrovascular diseases,16 or a comparatively
small study cohort.15–17 One study has found that fibrino-
gen predicts coronary heart disease in Asian countries
including Japan,19 but the association between silent cere-
brovascular lesions and fibrinogen in the Asian general
population has not been described.
Hypertension is a major risk factor for silent cerebrovas-
cular lesions,18,20 and ambulatory blood pressure (ABP) is
more closely correlated with target organ damage than casual
blood pressure (CBP).21,22
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We conducted a cross-sectional study to determine the
association between plasma fibrinogen and silent cerebrovas-
cular lesions in a general population. We also evaluated the
association between silent cerebrovascular lesions and the
risk conferred by combined fibrinogen and ABP levels.
Methods
Design
This investigation was a part of the Ohasama study. The socioeco-
nomic and demographic characteristics of this region and full details
of the project have been described elsewhere.23 The study protocol
was approved by the Institutional Review Board of Tohoku Univer-
sity School of Medicine, Sendai, Japan, and by the Department of
Health of the Ohasama Town Government.
Study Population
The population of Ohasama in 1998 was 7202. Of those, 3077 were
55 years or older. Individuals (n492) who were not at home during
the normal working hours of the study nurses, and those hospitalized,
mentally ill, or bedridden (n185), were not eligible for inclusion.
Of the remaining 2400 eligible individuals, 1174 subjects (49%)
gave informed consent and participated in the MRI examination. We
excluded 173 subjects whose BP and fibrinogen levels were not
adequately measured. We also exclude 43 subjects with history of
previous stroke or transient ischemic attack. Therefore, a total of 958
individuals (40%; mean age 66.05.7 years; 32% men) were
included in the present analysis.
MRI
We obtained MR images using a superconducting magnet with a
main 0.5 T. The brain was imaged in the axial plane in 10-mm-thick
slices and we collected T1- and T2-weighted images. A lacunar
infarct was defined as an area of low signal intensity measuring
15 mm and3 mm on T1-weighted images and that was visible as
a hyperintense lesion on T2-weighted images. Hyperintense punctate
lesions evident only on the T2-weighted images were not counted as
lacunar infarcts. We defined WMH as hyperintensities on only
T2-weighted images, and graded it according to Fazekas24 as
follows: absent (grade 0), punctate (grade 1), early confluent (grade
2), and confluent (grade 3). Small caps (510 mm) on the horns
of the lateral ventricles and pencil-thin lining around the ventricles
were considered normal. Larger caps (510 mm) were considered
as grade 2. A neurosurgeon and 4 technical experts directed by the
neurosurgeon independently evaluated the MRI findings in a blinded
manner. In the case of disagreement, a consensus reading was held.
Both intra-reader and inter-reader studies (n111) showed good
agreement. Kappa statistics were between 0.68 and 0.86 for lacunar
infarct, and between 0.72 and 0.86 for WMH. We defined silent
cerebrovascular lesions as: (1) WMH of grade 1 or more; (2)
presence of lacunar infarcts; or (3) any combination of
these findings.
BP Measurements
ABP was monitored using a fully automatic ABPM630 device
(Nippon Colin, Komaki, Japan)25 preset to measure BP every 30
minutes. Mean 24-hour, daytime, and nighttime values for ABP were
calculated for each participant. Daytime and nighttime values were
estimated from the subjects’ diaries.
CBP was measured twice consecutively in the sitting position,
after a minimum 2-minute interval of rest, by a doctor using a
mercury sphygmomanometer or an automatic device (HEM907;
Omron Healthcare Co. Ltd, Kyoto, Japan) at the time of MRI
examination. The average of the 2 readings was defined as the CBP.
Devices used to measure ABP and CBP have been validated25,26
and met the criteria of Association for the Advancement of Medical
Instrumentation.27
Physical and Biochemical Examination
Fibrinogen (mg/dL) was measured by the Clauss method. Hypercho-
lesterolemia was defined as total cholesterol 220 mg/dL, use of
medication for hypercholesterolemia, and/or a history of hypercho-
lesterolemia. Diabetes mellitus was defined as a nonfasting glucose
level of 200 mg/dL, HbA1c level of 6.5%, use of medication for
diabetes, and/or a history of diabetes mellitus.
Statistical Analysis
To analyze the relationship between silent cerebrovascular lesions
and patient characteristics, we used the 2 test for categorical data
and the Student t test for continuous data. We examined the
associations between fibrinogen and silent cerebrovascular lesions
using logistic regression analysis. Quartiles were initially analyzed,
where the lowest quartile was treated as the reference category. We
then entered fibrinogen as a linear term (per SD) into the model. We
adjusted for age (continuous variable), sex (men, women), cardio-
vascular risk factors including smoking status (ever, never), drinking
status (ever, never), use of antihypertensive medication (treated,
untreated), body mass index (25 kg/m2, 25 kg/m2), 24-hour ABP
(continuous variable), and a history of hypercholesterolemia, diabe-
tes mellitus, and atrial fibrillation (present, absent). We also exam-
ined the combination of fibrinogen and 24-hour ABP levels using
logistic regression analysis. All statistical analyses were conducted
using SAS software, version 9.1 (SAS Institute Inc, Cary, NC).
Values are expressed as meansSD. P0.05 was considered statis-
tically significant.
Results
Fibrinogen and Silent Cerebrovascular Lesions
Individuals with silent cerebrovascular lesions were signifi-
cantly older, had higher frequencies of use of antihyperten-
sive medication, cardiovascular disease, lower body mass
index, and higher 24-hour, daytime, nighttime ABP (both
systolic and diastolic BP), and fibrinogen levels (Table 1). In
individuals with silent cerebrovascular lesions, serum creati-
nine levels were significantly higher. Other biochemical
factors were not associated with silent cerebrovascular
lesions.
Figure 1 shows the adjusted odds ratios (ORs) and 95% CIs
for silent cerebrovascular lesions among the quartiles of
fibrinogen. The highest quartiles of fibrinogen were associ-
ated with a significant increase in the risk for silent cerebro-
vascular lesions (OR, 1.99; 95% CI, 1.34 to 2.97; P0.0007).
The associations were also similar for WMH and lacunar
infarct, respectively (Figure 2a, 2b). The highest quartiles of
fibrinogen were associated with a significant increase in the
risk for WMH (OR, 1.78; 95% CI, 1.20 to 2.65; P0.004)
and lacunar infarct (OR, 1.70; 95% CI, 1.09 to 2.65; P0.02).
The logistic regression analysis showed that more ad-
vanced age, use of antihypertensive medication, lower body
mass index, higher 24-hour ABP, and fibrinogen levels were
significantly associated with silent cerebrovascular lesions
(Table 2). Each 1-SD (62.0 mg/dL) increase in fibrinogen
was significantly associated with a risk for silent cerebrovas-
cular lesions (OR, 1.26; 95% CI, 1.09 to 1.46; P0.001).
When daytime or nighttime ABP or CBP was adapted to this
model instead of 24-hour ABP, the trends were similar,
although CBP was not significantly associated with silent
cerebrovascular lesions (data not shown). When 24-hour ABP
and CBP were adapted to the same model, the trends were
similar, although only CBP was not significantly associated
with silent cerebrovascular lesions (data not shown). The
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associations were also similar for WMH and lacunar infarct,
respectively (data not shown).
Other biochemical factors were not significantly associated
with silent cerebrovascular lesions in the multivariate analy-
sis (P0.08).
We also performed stratified analysis. Sex (men/women),
age (65 /65 years), and use of antihypertensive medica-
tion (treated/untreated) did not significantly interact the
association between fibrinogen and silent cerebrovascular
lesions (all P for interaction 0.2).
Association of 24-Hour ABP and Plasma
Fibrinogen Levels With the Risk of Silent
Cerebrovascular Lesions
Higher fibrinogen (328 mg/dL) and higher 24-hour ABP
(135/80 mm Hg28) levels were independently associated
with an increase risk for silent cerebrovascular lesions (Fig-
ure 3). Even when 24-hour ABP values were within normal
range (135/80 mm Hg), elevated fibrinogen levels were
associated with an increased risk of silent cerebrovascular
lesions. There were no significant interactions between 24-
hour ABP and fibrinogen on the risk of silent cerebrovascular
lesions (P0.8). Fibrinogen and 24-ABP had additive effects
on silent cerebrovascular lesions.
Discussion
The present cross-sectional study found that 24-hour ABP
and fibrinogen levels were significantly and independently
associated with prevalence of silent cerebrovascular lesions,
including WMH and lacunar infarct, in a comparatively large
general population.
TABLE 1. Population Characteristics (Ohasama Study, Japan, 1998)
Silent Cerebrovascular Lesions
() () P
N of subjects 492 466
Men, % 29 34 0.1
Age, y 645 685 0.0001
BMI, kg/m2 243 233 0.03
BP, mm Hg
Ambulatory 24-hour Systolic 12312 12813 0.0001
Diastolic 727 747 0.0001
Daytime Systolic 12913 13414 0.0001
Diastolic 768 788 0.0001
Nighttime Systolic 11113 11714 0.0001
Diastolic 637 668 0.0001
Casual Systolic 14021 14220 0.09
Diastolic 7811 7811 0.9
Ever smoker, % 17 21 0.07
Ever drinker, % 28 30 0.6
Antihypertensive medication, % 26 50 0.0001
Hypercholesterolemia, % 36 38 0.6
Diabetes, % 14 17 0.2
Cardiovascular disease, % 7 12 0.007
Atrial fibrillation, % 2 3 0.3
Biochemical value
Fibrinogen, mg/dL 28954 30669 0.0001
Hematocrit, % 424 424 0.2
Total cholesterol, mg/dL 20033 20133 0.5
HDL cholesterol, mg/dL 5715 5616 0.8
Triglyceride, mg/dL 13379 12878 0.3
Lipoprotein(a), mg/dL 2323 2425 0.5
Serum creatinine, mg/dL 0.770.16 0.820.22 0.0001
Uric acid, mg/dL 4.41.2 4.51.3 0.3
High-sensitivity CRP, mg/L 0.39 (0.18–0.79) 0.47 (0.21–0.85) 0.5
Values for high-sensitivity CRP levels are medians (interquartile range).
N of biochemical examination: fibrinogen and lipoprotein(a), 958; hematocrit, 901; total cholesterol and triglyceride,
946; HDL cholesterol, 900; serum creatinine, 939; uric acid, 931; high-sensitivity CRP, 224.
BMI indicates body mass index; BP, blood pressure; CRP, C-reactive protein; HDL, high-density lipoprotein.
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The findings of previous studies15–18 that investigated the
association between fibrinogen and silent cerebrovascular
lesions are inconsistent. For example, Schmidt et al15 found
that higher fibrinogen levels are associated with WMH and
lacunes in a multivariate analysis of 349 individuals. Mean-
while, in a population-based study of 3301 elderly individu-
als, Longstreth et al18 found that fibrinogen levels were not
independently related to white matter grade in fully adjusted
multivariate models. In this study, associations between
fibrinogen and silent cerebrovascular lesions remained statis-
tically significant even after adjustment for various confound-
ing variables in the general population.
Recently, Sato et al demonstrated in a prospective study of
Japanese subjects with no history of stroke and/or coronary
heart disease that high plasma fibrinogen concentration was a
predictor for risk of intraparenchymal hemorrhage but not of
cerebral infarction.14 However, the clear mechanism respon-
sible to the difference between cerebral hemorrhage and
cerebral infarction was not described. The present study
found that fibrinogen levels were associated with silent
cerebrovascular lesions. Because silent cerebrovascular le-
sions constitute an independent predictor of the risk of
cerebral infarction,1 it is possible that fibrinogen would be a
risk of cerebral infarction. We are following-up the present
subjects to clarify this question.
The exact mechanism by which elevated fibrinogen might
contribute to WMH and lacunar infarct remains unknown.
However, these lesions are considered to reflect ischemic
small vessel disease. Fibrinogen triggers a variety of athero-
genic processes such as endothelial injures.10 Thus, fibrino-
gen might promote atherogenesis not only in large vessels but
also in small vessels. Elevated fibrinogen levels induce a state
of hypercoagulability,6,7 and might reflect the progression of
atherosclerosis. Such hemorheological impairments caused
by increased levels of fibrinogen would aggravate cerebral
hypoperfusion.
Hyperfibrinogenemia can be alleviated using drugs and by
making lifestyle modifications, such as stopping smoking and
starting to exercise.29 Fibrinogen levels are inversely associ-
ated with dietary consumption of seafood.30 Miura et al
reported that higher intake of iron, sugar, and caffeine, in
addition to obesity, account largely for higher fibrinogen
levels.31 Several drugs reduce fibrinogen levels, including
bezafibrate and ticlopidine.4,5,32 However, no reliable evi-
dence yet supports the routine use of fibrinogen-lowering
agents to reduce the risk of cerebrovascular diseases. Further
study is needed to clarify this issue.
The present study indicated that ABP values are more
closely associated with silent cerebrovascular lesions than
with 2 measurements of CBP at one visit. This finding is
consistent with those of a previous study.22 Furthermore, the
present study discovered that 24-hour ABP and plasma
fibrinogen levels are closely and independently associated
with a risk of silent cerebrovascular lesions. Even when
24-hour ABP values were within normal range, elevated
fibrinogen levels were associated with an increased risk of
silent cerebrovascular lesions. These findings suggest that
both factors are strong risk factors for silent cerebrovascular
lesions.
Possibility of selection bias needs to be considered to
generalize the present findings, because there were differ-
ences in age between the study subjects and those excluded
(958 study subjects, 66.05.7 years; 216 excluded subjects,
69.27.0 years; P0.0001). In addition, marked differences
exist in the epidemiologies of cerebrovascular disease be-
tween Japan and US or European countries. Further research
Figure 1. Adjusted ORs and 95% CIs for silent cerebrovascular
lesions among the quartiles of fibrinogen. ORs for silent cere-
brovascular lesions were adjusted for age, sex, smoking status,
drinking status, use of antihypertensive medication, body mass
index, 24-hour ABP, and history of hypercholesterolemia, diabe-
tes mellitus, and atrial fibrillation. Cut-off for quartiles of fibrino-
gen: 1st, 258 mg/dL; 2nd, 259 to 292 mg/dL; 3rd, 293 to 327
mg/dL; 4th, 328 mg/dL. *P0.05 vs. 1st quartile.
Figure 2. Adjusted ORs and 95% CIs for (a) WMH and (b) lacu-
nar infarct among the quartiles of fibrinogen. ORs for (a) WMH
and (b) lacunar infarct were adjusted for age, sex, smoking sta-
tus, drinking status, use of antihypertensive medication, body
mass index, 24-hour ABP, and history of hypercholesterolemia,
diabetes mellitus, and atrial fibrillation. Cut-off for quartiles of
fibrinogen: 1st, 258 mg/dL; 2nd, 259 to 292 mg/dL; 3rd, 293
to 327 mg/dL; 4th, 328 mg/dL. *P0.05 vs. 1st quartile.
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in other ethnic and cultural populations is needed to confirm
the generalizability of our findings.
In conclusion, the present study demonstrated that 24-hour
ABP and plasma fibrinogen levels are closely and indepen-
dently associated with the risk of silent cerebrovascular
lesions, suggesting that fibrinogen is an independent risk
factor or predictor of silent cerebrovascular lesions.
Sources of Funding
This work was supported by grants for Scientific Research
(15790293, 17790382, 18390192, and 18590587) from the Ministry
of Education, Culture, Sports, Science, and Technology, Japan;
grant-in-aid for Japan Society for the Promotion of Science (JSPS)
fellows (16.54041, 18.54042); Health Science research grants and
Medical Technology Evaluation research grants from the Ministry of
Health, Labor, and Welfare, Japan; Japan Atherosclerosis Prevention
Fund; Uehara Memorial Foundation; and Takeda Medical Research
Foundation.
Disclosures
None.
References
1. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ,
Breteler MM. Silent brain infarcts and white matter lesions increase
stroke risk in the general population: the Rotterdam Scan Study.
Stroke. 2003;34:1126–1129.
2. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical
silent brain infarction as a risk factor for clinical stroke. Stroke. 1997;28:
1932–1939.
3. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler
MM. Silent brain infarcts and the risk of dementia and cognitive decline.
N Engl J Med. 2003;348:1215–1222.
4. Drouet L. Fibrinogen: a treatable risk factor? Cerebrovasc Dis. 1996;
6:2–6.
5. Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs.
1997;54(Suppl 3):32–40.
6. Fisher M, Meiselman HJ. Hemorheological factors in cerebral ischemia.
Stroke. 1991;22:1164–1169.
7. Iwamoto T, Kubo H, Takasaki M. Platelet activation in the cerebral
circulation in different subtypes of ischemic stroke and Binswanger’s
disease. Stroke. 1995;26:52–56.
8. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk
of cardiovascular disease. The Framingham study. JAMA. 1987;258:
1183–1186.
9. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L,
Tibblin G. Fibrinogen as a risk factor for stroke and myocardial
infarction. N Engl J Med. 1984;311:501–505.
10. Di Minno G, Mancini M. Measuring plasma fibrinogen to predict stroke
and myocardial infarction. Arteriosclerosis. 1990;10:1–7.
11. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of
major cardiovascular diseases and nonvascular mortality: an individual
participant meta-analysis. JAMA. 2005;294:1799–1809.
12. Moons KG, Bots ML, Salonen JT, Elwood PC, Freire de Concalves A,
Nikitin Y, Sivenius J, Inzitari D, Benetou V, Tuomilehto J, Koudstaal PJ,
Grobbee DE. Prediction of stroke in the general population in Europe
(EUROSTROKE): Is there a role for fibrinogen and electrocardiography?
J Epidemiol Community Health. 2002;56(Suppl 1):i30–i36.
13. Kofoed SC, Wittrup HH, Sillesen H, Nordestgaard BG. Fibrinogen
predicts ischaemic stroke and advanced atherosclerosis but not
echolucent, rupture-prone carotid plaques: The Copenhagen City Heart
Study. Eur Heart J. 2003;24:567–576.
14. Sato S, Iso H, Noda H, Kitamura A, Imano H, Kiyama M, Ohira T, Okada
T, Yao M, Tanigawa T, Yamagishi K, Nakamura M, Naito Y, Shimamoto
TABLE 2. Multivariate ORs and 95% CIs for Silent Cerebrovascular Lesions With
Carodiovascular Risk Factors
OR 95% CI P
Sex, men (n303):women (n655) 1.01 0.64–1.60 1.0
Age, per 10-year increase 2.90 2.22–3.80 0.0001
Smoker, ever smokers (n181):never smokers (n777) 1.19 0.74–1.90 0.5
Drinker, ever drinkers (n276):never drinkers (n682) 1.19 0.80–1.79 0.4
Diabetes, present (n149):absent (n809) 1.06 0.72–1.55 0.8
Hypercholesterolemia, present (n356):absent (n602) 1.20 0.89–1.61 0.2
Atrial fibrillation, present (n27):absent (n931) 1.06 0.44–2.52 0.9
Antihypertensive medication, treated (n362):untreated (n596) 2.02 1.49–2.75 0.0001
BMI, 25 kg/m2 (n305):25 kg/m2 (n653) 0.72 0.53–0.97 0.03
24-hour average ambulatory SBP, per 10-mm Hg increase 1.23 1.10–1.39 0.0006
Fibrinogen, per 1-SD increase 1.26 1.09–1.46 0.001
SBP indicates systolic blood pressure.
These variables were simultaneously included multiple logistic regression model.
Figure 3. Adjusted ORs and 95% CIs (inside the bars) for silent
cerebrovascular lesions associated with combination of fibrino-
gen levels and 24-hour ABP levels. ORs for silent cerebrovascu-
lar lesions were adjusted for age, sex, smoking status, drinking
status, use of antihypertensive medication, body mass index,
and history of hypercholesterolemia, diabetes mellitus, and atrial
fibrillation. nnumber of participants in group. Higher fibrinogen
was defined 328 mg/dL (dichotomized at upper quartiles).
Normal 24-hour ABP is defined as 24-hour ABP levels
135/80 mm Hg.
Aono et al Fibrinogen and Silent Cerebrovascular Lesions 967
 at TOHOKU UNIVERSITY on September 1, 2011http://atvb.ahajournals.org/Downloaded from 
T. Plasma fibrinogen concentrations and risk of stroke and its subtypes
among Japanese men and women. Stroke. 2006;37:2488–2492.
15. Schmidt R, Fazekas F, Hayn M, Schmidt H, Kapeller P, Roob G,
Offenbacher H, Schumacher M, Eber B, Weinrauch V, Kostner GM,
Esterbauer H. Risk factors for microangiopathy-related cerebral damage
in the Austrian stroke prevention study. J Neurol Sci. 1997;152:15–21.
16. Tsuda Y, Satoh K, Kitadai M, Takahashi T. Hemorheologic profiles of
plasma fibrinogen and blood viscosity from silent to acute and chronic
cerebral infarctions. J Neurol Sci. 1997;147:49–54.
17. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den
Hout JH, van Harskamp F, Tanghe HL, de Jong PT, van Gijn J, Hofman
A. Cerebral white matter lesions, vascular risk factors, and cognitive
function in a population-based study: The Rotterdam study. Neurology.
1994;44:1246–1252.
18. Longstreth WT Jr., Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis
CA, Enright PL, O’Leary D, Fried L, for the Cardiovascular Health Study
Collaborative Research Group. Clinical correlates of white matter
findings on cranial magnetic resonance imaging of 3301 elderly people:
The Cardiovascular Health Study Stroke. 1996;27:1274–1282.
19. Sato S, Nakamura M, Iida M, Naito Y, Kitamura A, Okamura T,
Nakagawa Y, Imano H, Kiyama M, Iso H, Shimamoto T, Komachi Y.
Plasma fibrinogen and coronary heart disease in urban Japanese. Am J
Epidemiol. 2000;152:420–423.
20. Lee SC, Park SJ, Ki HK, Gwon HC, Chung CS, Byun HS, Shin KJ, Shin
MH, Lee WR. Prevalence and risk factors of silent cerebral infarction in
apparently normal adults. Hypertension. 2000;36:73–77.
21. Sokolow M, Werdegar D, Kain HK, Hinman AT. Relationship between
level of blood pressure measured casually and by portable recorders and
severity of complications in essential hypertension. Circulation. 1966;34:
279–298.
22. Shimada K, Kawamoto A, Matsubayashi K, Ozawa T. Silent cerebro-
vascular disease in the elderly. Correlation with ambulatory pressure.
Hypertension. 1990;16:692–699.
23. Imai Y, Nagai K, Sakuma M, Sakuma H, Nakatsuka H, Satoh H, Minami
N, Munakata M, Hashimoto J, Yamagishi T, Watanabe N, Yabe T,
Nishiyama A, Abe K. Ambulatory blood pressure of adults in Ohasama,
Japan. Hypertension. 1993;22:900–912.
24. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F,
Rander H, Lechner H. Pathologic correlates of incidental MRI white
matter signal hyperintensities. Neurology. 1993;43:1683–1689.
25. Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Sekino H, Nihei M,
Yoshinaga K. Determination of clinical accuracy and nocturnal blood
pressure pattern by new portable device for monitoring indirect ambu-
latory blood pressure. Am J Hypertens. 1990;3:293–301.
26. White WB, Anwar YA. Evaluation of the overall efficacy of the Omron
office digital blood pressure HEM-907 monitor in adults. Blood Press
Monit. 2001;6:107–110.
27. Association for the Advancement of Medical Instrumentation. Am
national standards for electronic or automated sphygmomanometers.
Washington, DC. AAMI Analysis and Review. 1987.
28. Guidelines Subcommittee of the Japanese Society of Hypertension.
Japanese Society of Hypertension Guidelines for the Management of
Hypertension (JSH 2004). Hypertens Res. 2006;29 (Suppl):S1–S105.
29. Wannamethee SG, Lowe GDO, Whincup PH, Rumley A, Walker M,
Lennon L. Physical activity and hemostatic and inflammatory variables in
elderly men. Circulation. 2002;105:1785–1790.
30. Sato S, Iso H, Naito Y, Kiyama M, Kitamura A, Iida M, Shimamoto T,
Komachi Y. Plasma fibrinogen and its correlates in urban Japanese men.
Int J Epidemiol. 1996;25:521–527.
31. Miura K, Nakagawa H, Ueshima H, Okayama A, Saitoh S, Curb JD,
Rodriguez BL, Sakata K, Okuda N, Yoshita K, Stamler J; for the
INTERMAP and INTERLIPID Research Groups. Dietary factors related
to higher plasma fibrinogen levels of Japanese-americans in Hawaii
compared with Japanese in Japan. Arterioscler Thromb Vasc Biol. 2006;
26:1674–1679.
32. Tanne D, Benderly M, Goldbourt U, Boyko V, Brunner D, Graff E,
Reicher-Reiss H, Shotan A, Mandelzweig L, Behar S; the Bezafibrate
Infarction Prevention Study Group. A prospective study of plasma
fibrinogen levels and the risk of stroke among participants in the Beza-
fibrate Infarction Prevention Study. Am J Med. 2001;111:457–463.
968 Arterioscler Thromb Vasc Biol. April 2007
 at TOHOKU UNIVERSITY on September 1, 2011http://atvb.ahajournals.org/Downloaded from 
